Recent evidence suggests that the drug-transport molecule P-glycoprotein (P-gp) encoded by the multi-drug resistance (mdr) gene, may play a causative role in refractory epilepsy. We have conducted a pharmacokinetic investigation of eight antiepileptic drugs (AEDs) in genetically modified mdr1a(−/−) knock-out mice device of P-gp at the blood-brain barrier.
Non-epileptic seizures following general anaesthetics
Ida Lichter, B. Toone & J. Mellers
Maudsley Hospital, Denmark Hill, London SE5 8AZ, UK
Although post-operative seizures are rare, cases of seizure-like disorders, sometimes lasting up to several weeks, have been described particularly in association with propofol anaesthesia. Clinical features included opisthotonus and other dystonias.
Five patients who developed seizures following a general anaesthetic are described. All patients attended the Neuropsychiatry Epilepsy Unit at the Maudsley Hospital and King's College Hospital. Three patients had a history of anxiety, depression and sexual abuse. In all cases, repeated seizures followed the initial attack and descriptions of clinical features were characteristic of dissociative attacks. In addition, neurological examination was normal and ictal EEG's captured during video-telemetry or photic stimulation showed well-preserved alpha rhythm and no epileptiform changes. Although in retrospect, it is not possible to determine whether the initial attacks were epileptic, subsequently these patients had a firm diagnosis of pseudoseizures. In two cases where interictal EEGs showed some abnormality, it is possible that both epileptic and pseudoepileptic seizures co-existed.
We suggest that anaesthetic agents may trigger pseudoseizures by inducing a state of altered awareness, particularly in vulnerable personalities, and that a psychogenic basis for seizures occurring after general anaesthesia needs to be considered. 
INVESTIGATION

Magnetic Resonance & Image Analysis Research Centre, University of Liverpool, Pembroke Place, Liverpool L69 3BX, UK
Introduction: It is well established that hippocampal sclerosis (HS) is characterised by selective neuronal cell loss and reactive gliosis, suggesting it is unlikely that one will occur without the other in the majority of Temporal Lobe Epilepsy (TLE) patients. The aim of this study was to examine the extent to which increased hippocampal T2 relaxation time and reduced hippocampal volume were both present on MRI in TLE patients with a histopathological diagnosis of HS.
Method: A FSE imaging sequence was acquired along the long axis of the hippocampus using a 1.5 SIGNA whole body MR imaging system.
Results:
Thirty-six out of 68 post-surgical patients had a histopathological diagnosis of medial temporal sclerosis (MTS). In this group, 14 inconsistencies were noted, volume asymmetry (atrophy) was lateralising in 35 (97%) cases, in 22 (61%) patients, T2 relaxation agreed with the volumetry. However, T2 relaxation time alone failed to lateralise MTS. In one case, volumetry and T2 relaxation time both failed to identify MTS. Discussion: T2 relaxation time is a valuable indicator of hippocampal sclerosis. However, patients with histological HS and an ipsilateral decrease in hippocampal volume do not always have an increase in T2 relaxation time. Observed differences in T2 could be due to bilateral sclerosis, non-specific increases in water content, myelin abnormalities, unidentified dual pathology and varying degrees of hippocampal sclerosis. 
Voxel based morphometry of hippocampal and extra hippocampal effects of unilateral temporal lobe epilepsy
Methods:
Patients had surface EEG (sEEG), Wada test and qMRI (measurements of hippocampal volume and T2 relaxation time). FOR were performed if sEEG was not lateralising or qMRI was normal. We compared the outcome of three groups: I. Patients with FOR and normal qMRI (n = 16), II. Patients with FOR and hippocampal abnormalities on qMRI (n = 41), III. Patients without FOR and hippocampal abnormalities on qMRI (n = 29).
Results:
In group I, 15 of 16 patients were rejected because FOR failed to identify the seizure onset zone, 1 patient failed surgery. In group II, 12 of 41 patients became seizure free after surgery, 13 failed surgery, 16 were rejected in group III, 16 of 29 patients became seizure free, 5 failed surgery and 8 were rejected. The 3 groups were significantly different with respect to outcome (P < 0.001).
Conclusion: FOR are of limited, if any, value in patients with no abnormality on qMRI. FOR may have a role in patients with hippocampal abnormalities on qMRI but non-lateralising surface EEG. Introduction: Vigabatrin is an antiepileptic drug that acts by irreversibly binding to GABA-T causing an increase in GABA available in the brain. Since 1997, an increasing number of studies have been linking vigabatrin to a specific pattern of peripheral visual field loss in one-third of patients. The majority of studies have not included a paediatric population due to difficulties assessing visual field function using standard perimetry tests in those children with a developmental age below nine years. This is a particular problem as vigabatrin is effective against infantile spasms.
SIDE-EFFECTS
Methods:
A field-specific visual evoked potential (the H-Stimulus), was developed which consisted of a central stimulus (0-5 • radius), a blank annulus and a peripheral stimulus (30-60 • radius). Both the central and peripheral stimuli consist of black and white checks that increase in size with eccentricity. The checks reverse at different rates allowing for two responses to be recorded monocularly from O2 and O1 referred to Fz. Thirty-nine children, aged 3-15 years, were included in the study, with perimetry carried out as a comparison.
Results: Thirty-five children complied with the H-Stimulus but only 11 could perform perimetry. Using the summed amplitude of the peripheral response from O2 and O1, any responses below 10 µv were deemed abnormal. The H-Stimulus identified 3/4 abnormal perimetry results and 6/7 normal perimetry results, giving a sensitivity of 75% and a specificity of 85.7%.
Conclusions:
The H-Stimulus is a useful alternative method to perimetry that is both well tolerated by young children and gives a reliable indication of possible peripheral visual fields loss. Methods: Our recent prospective study of pregnant women with epilepsy identified 300 women who completed a questionnaire about their epilepsy, drug treatment and education.
292 women consented to developmental assessment of their children prior to delivery. These infants are being visited by a paediatrician (blinded to the maternal history) and assessed using Bayley's scales of development. Assessments are made in the third year. Development of these children is then compared to that of the general population.
Results: 111 infants have been examined to date: 78 born to mothers on monotherapy (carbamazepine 38, valproate 40), 23/111 (21%) infants have delayed development (P = 0.0215), 8 having severe delay (7.2%, population prevalence 1.5% P = 0.0006). Developmental delay is associated not only with carbamazepine monotherapy (P = 0.02) and valproate (P = 0.005) in pregnancy but also with lower maternal educational achievement; only 30% of mothers of delayed children obtained 5 GCSE passes (A-G) compared to 85% general population (P = 0.0118).
Conclusion:
Children born to mothers with epilepsy are at greater risk of delay but the cause is likely to be multifactorial including maternal education and socioeconomic factors.
Possible beneficial effect of lamotrigine on function and structure of the ovary in women with epilepsy who have the polycystic ovary syndrome
Birmingham University Seizure Clinic, Queen Elizabeth Psychiatric Hospital, Birmingham B15 2QZ, UK
Women with epilepsy, particularly if they acquire it in childhood or adolescence, are more likely to have both polycystic (polyfollicular) ovaries and the polycystic ovary syndrome than their non-epileptic peer group. This may be due to a direct epilepsy effect on brain hormone releasing mechanisms. We have some evidence to suggest that women with 'epilepsy induced' polycystic ovaries may be more likely to develop the polycystic ovary syndrome if on valproate monotherapy (Betts and Yarrow, 2000) , the hormonal parameters of the syndrome may return to normal if the valproate is withdrawn.
During preconceptual substitution of valproate for lamotrigine we have recently observed, in four women, that hormonal parameters return to normal almost immediately on the exhibition of lamotrigine before the withdrawal of the valproate. Marked resolution of the size and number of cysts in the ovaries has also been observed after a year. This latter observation might be, of course, just be a valproate withdrawal effect.
This intriguing observation has been reinforced by a study of a patient who already had hormonal and scanning evidence of a long-standing polycystic ovary syndrome with very irregular menstruation before developing epilepsy and commencing lamotrigine. Shortly after starting lamotrigine she began to menstruate regularly, hormonal parameters returned to normal and re-scanning of her ovaries after a year of being on lamotrigine showed that the size of her ovaries had reduced, as had the size and number of cysts.
If this intriguing finding is reproduced in a larger sample we will need to speculate about the mechanisms involved. Is it a direct effect of lamotrigine on the ovary, or on midbrain hormone releasing mechanisms, or something like a metformin effect?
Effect of three drugs (valproate, lamotrigine and carbamazepine) on ovarian structure and function when used in exclusive monotherapy in women with primary generalised epilepsy
We have been studying ovarian structure and function in young women presenting to our clinic with primary generalised epilepsy, mostly for preconception counselling. We have examined the results in three groups of women who have only ever taken valproate, carbamazepine or lamotrigine.
The prevalence of polycystic (polyfollicular) ovaries is high in this group of women, almost certainly higher than one would expect in a normal population of women. There is no difference in the prevalence of polycystic (polyfollicular) ovaries in the three patient groups suggesting that this increased prevalence is an epilepsy effect rather than a specific drug effect.
There was, however, a highly significant difference in the prevalence of the polycystic ovary syndrome in the three groups only women taking valproate in monotherapy, possessing polyfollicular ovaries, had the hormonal characteristics of the syndrome (there is also clear evidence that the hormonal changes of the syndrome regress if the valproate is withdrawn).
Our interim conclusions are that polycystic ovaries are commoner in women with epilepsy than one would expect by chance but presumably due to putative effects of epilepsy on midbrain hormone releasing mechanisms; such women may be vulnerable to some metabolic effect of valproate itself which is reversible. This would suggest that women with epilepsy who have polycystic (polyfollicular) ovaries should avoid the use of valproate if possible. Methods: This is a retrospective review of 550 patients prescribed VGB between 1989 and 1998. Data is collected on dose/ duration of treatment, results of perimetry, as well as reason for and outcome of discontinuation.
Results: 42 (11%) of the first 400 patients analysed have been lost to follow up whilst still taking VGB. Another 36 (9%) continue on VGB and remain under review. Visual fields have been tested in 31 (40%) of these patients who may still be on VGB and were abnormal with no alternative cause in 13 (42%). Seizure control improved in 75 (23%) of those withdrawn from VGB while only 13 (4%) deteriorated, and 215 (67%) were unchanged.
Conclusions: Preliminary analysis reveals that 20% of those treated with VGB remain on treatment despite the potential serious visual adverse effects. While visual defects are common in those tested, 54% are not being monitored or counselled. There are significant cost implications in adherence to guidelines of those staying on treatment and in tracing/assessing those lost to follow-up. Given that switch over rarely results in deterioration, there is a good case for cessation of VGB in most, if not all, individuals. Rationale: Once a Consultant prescribes an AED it is expected that the nurse will be monitoring side-effects. Doctors are regularly provided with B.N.F.'s, but nurses are expected to monitor without up-to-date information. Will providing nurses with AED monitoring checklists increase the detection of harmful side-effects?
NURSING
Method: Twenty RNLD presently monitoring AED's were surveyed using a simple questionnaire on known common sideeffects of medication and possible clinical signs.
Results:
• Two nurses thought Largactil was an AED.
• One nurse said if people didn't become ill, they had no side-effects.
• 3/4 of nurses were unaware of any link with AED's on the menstrual cycle or interaction with the pill.
• Only two nurses were aware that AED's are available in Brand and proprietary formulations.
Conclusion:
Introducing a nurses AED checklist would enable early detection of side-effects and enhance the service provided. The recent Clinical Standards Advisory Group report has criticised the conventional care given to epilepsy patients. It found that there was strong support for Epilepsy Specialist Nurses whose numbers have been increasing since 1988, and mentioned Telemedicine as a possible way of improving the service to patients.
In Northern Ireland we have shown that Telemedicine, using interactive video consultation, is a safe and effective way to deal with both acute neurological admissions and new neurological outpatients.
Epilepsy centres, as envisaged in the CSAG report may not be practical in widely scattered rural communities, and so we decided to use a nurse-led approach with graduated Telemedicine support from a Consultant Neurologist in two rural hospitals.
We present the findings of a pilot study.
To date 16 patients have been studied in a graduated way, first by the nurse alone, second, if necessary, with a telephone call to the Neurologist and third, if necessary with video conferencing to the Neurologist.
40% of the patients were managed by the nurse alone, with only 20% requiring video link to Neurologist. Patient satisfaction in all groups was high with all agreeing to be seen that way in future. This graduated approach deserves further study as a way of optimising epilepsy care in rural areas.
'What a difference a nurse makes'
Jan It is estimated that more than 30 000 people in Scotland have epilepsy. There are few true epilepsy specialists for these people to see. Many people with epilepsy will never see a specialist but will have their condition managed by their General Practitioner. With this in mind the Practice Nurse has been identified as potentially being a key resource in optimising the care of those with epilepsy. Recognising that nurses receive very little information about epilepsy during their training, the first annual Short Course in Epilepsy for Practice Nurses in Scotland was held in 1998. The course was organised and run by two epilepsy specialist nurses in Glasgow.
There have been 3 four-day courses run with a total of 71 nurses attending. Epilepsy knowledge before and after was assessed using the Epilepsy Knowledge Questionnaire. A follow-up survey shows marked improvement in epilepsy awareness audit in primary care and patient review. Results show the magnitude of the potential improvement in services, discussion covers course content and nurse's epilepsy knowledge. It is concluded that the value of this course to people with epilepsy is immensely important and that epilepsy specialist nurses have a major role in providing education. We have run for some years a fast track clinic in our service for people with new onset seizures diagnosed as epilepsy by their general practitioners, based on our one-stop clinic (where the patient has an EEG, MRI scan, full history and examination the first time they come, with the second visit two or three weeks later to assess the results and to develop a treatment plan). Audit of such a clinic has shown that only 21% of presenting patients actually have epilepsy which means that many patients may be receiving unnecessary investigation. To supplement our service we therefore set up a nurse-led Triage clinic in which patients were seen very rapidly after referral for an assessment as to whether or not they needed full investigation. Only 15% of the 62 patients assessed had epilepsy for certain: in 22% the diagnosis was uncertain (and remained so on consultant review). The commonest non epilepsy diagnosis was syncope (30%). There was complete nurse/consultant diagnostic agreement. 41% had a subsequent EEG and 30% a subsequent MRI. This seemed to us therefore an effective use of our stretched resources until our accountants pointed out that acting more efficiently was actually costing us money. The inflexible nature of NHS funding means that for every one-stop patient seen and assessed we receive a fixed sum, some five times the amount of a single assessment in the Triage clinic. However, if 'Triage' patients then need further investigation this is not funded and the cost has to be met from our own resources. Nine months of a Triage clinic has already cost us over £20 000 and since the unit is critically dependent on external funding this has meant that we have had to abandon this new clinic. This lead us to ruefully conclude that our National Health Service, which successive politicians have demanded is run as a business, would have been bankrupt many years ago if it had any competitors in an open market.
TREATMENT
The risk of contracting malaria is high when travelling to some parts of the world, and prophylactic medicines are normally recommended to protect the traveller. These measures are especially important in people who have epilepsy because problems can occur when combining antimalarial and antiepileptic tablets.
Chloroquine (contained in Avloclor and Nivaquin) is one of the most widely used antimalarial preventative treatments, and mefloquine (Larium) is generally recommended when travelling to countries where the malarial parasite is resistant to chloroquine. The British National Formulary (BNF) advises people with epilepsy or a past history of epilepsy not to take these medications because they can cause seizures.
Two antimalarial drugs are available without prescription in the UK, proguanil (Paludrine) and chloroquine, and the Epilepsy Research Foundation was concerned that chloroquine might be made available to people with epilepsy despite being contraindicated. Results from a survey undertaken in 16 pharmacies found that they were incorrectly sold over the counter in 17% of cases. Concerns over teratogenicity of antiepileptic drugs (AED) must be balanced against the risks to the foetus of maternal seizures. AED compliance assessment by history or a single blood level cannot reliably reflect overall drug taking behaviour. We have assessed AED compliance in pregnant epilepsy patients compared to non-pregnant controls, using hair analysis to indicate drug taking behaviour.
15-20 hairs were cut from the posterior vertex scalp of 21 pregnant women (mean age 25.2 years) and 31 non-pregnant epilepsy outpatients (mean age 32.0 years; 13 female). Eight other pregnant women were excluded as, on valproate monotherapy, no hair assay is currently available. AED concentration (carbamazepine, lamotrigine) was measured in 1 cm hair segments by high performance liquid chromatography (HPLC). The coefficient of variation (%CV) of AED concentration between hair segments by subject was used to assess drug compliance.
Three of the 21 pregnant patients showed no AED in the proximal hair segments, the concentration having fallen rapidly in the first trimester; one later disclosed having stopped her prescribed AED. The remaining 20 showed compliance similar to non-pregnant controls (mean %CV 13.65 and 17.21 respectively [NS]).
In conclusion, these pregnant women mostly showed AED compliance similar to non-pregnant controls. A significant proportion (14%), however, had covertly discontinued AED after conception.
Phenytoin versus valproate monotherapy: a meta-analysis
A. Marson, C. Tudur & P. Williamson
Department of Neurological Science, Clinical Sciences Centre, Lower Lane, Fazakerley, Liverpool L9 7LJ, UK
Rationale: To overview the evidence from randomized controlled trials comparing phenytoin and valproate monotherapy.
Methods:
We report a meta-analysis using individual patient data. Our search included the Cochrane Library, Medline, handsearching relevant journals and contacting pharmaceutical companies. Outcomes were time to: (i) withdrawal of treatment, (ii) 12-month remission, (iii) first seizure. Results are expressed as hazard ratios (HR) with 95% confidence intervals. A HR > 1 indicated that an event is more likely on phenytoin.
Results: Data were available for 669 patients from five trials, representing 60% of the patients from the 11 trials that met our inclusion criteria. The main overall results (HR 95% Cl) were: (i) time to treatment withdrawal 0.96 (0.70-1.32), (ii) time to 12 month remission 1.04 (0.78-1.38), (iii) time to first seizure 0.92 (0.74-1.14). These results suggest no overall difference between drugs. A test for an interaction between drug and seizure type (generalized versus localization related) was also nonsignificant.
Conclusions:
We have found no evidence of an overall difference between phenytoin and valproate monotherapy and no evidence to support the belief of an interaction between drug and seizure type. If future trials are to inform practice, they need to be designed and powered accordingly. 
Birmingham University Seizure Clinic, Queen Elizabeth Psychiatric Hospital, Birmingham B15 2QZ, UK
As previously reported (Betts and Fox, 1999) (Betts, Morgan and Fox, 2000) , we currently attempt to switch women with epilepsy contemplating pregnancy from valproate to lamotrigine monotherapy.
A pilot audit of this practice suggests the following (46 patients).
(a) 56% of patients transferred from valproate monotherapy to lamotrigine monotherapy successfully but the process takes a long time and cannot be hurried. It was significantly more likely to be successful if the switch was carried out by a nurse specialist, and/or a consultant/nurse team, if blood levels monitoring and EEG monitoring were used; junior doctors and GPs were much less likely to carry the switch to completeness.
(b) We had used a linear model for decreasing the valproate dose and increasing the lamotrigine dose (decreases in valproate dosing and increases the lamotrigine dosing ran pari passu because valproate inhibits the metabolism of lamotrigine so that lamotrigine levels will paradoxically fall as valproate doses fall).
(c) Evidence from our own audit (and recent evidence from Sweden) suggests this may not be the most appropriate model. Most of the decrease in lamotrigine levels consequent upon withdrawal of valproate appears to occur towards the end of withdrawal and not in a linear fashion, resulting in some unexpected necessary increases in the lamotrigine dose after valproate has been completely withdrawn. Seizure control was often only maintained if the dose of lamotrigine was three times higher than at the start of valproate withdrawal.
Possible clinical effectiveness of levetiracetam on resistant photosensitivity-an early observational study Seizures evoked by photo or pattern sensitivity are a not uncommon problem, particularly in the adolescent. They are usually managed using either valproate or lamotrigine or, in resistant cases, a mixture of both drugs. Some patients, however, continue to exhibit clinically important photo or pattern sensitivity despite conventional drug treatment. The introduction of levetiracetam (Keppra) on to the market has enabled us to try it in a few patients with resistant photo or pattern sensitivity. The rationale for this was our previous observation that levetiracetam may be effective in some forms of resistant primary generalised epilepsy, particularly juvenile Myoclonic Epilepsy (with which photosensitivity is often associated). A previous single dose study also suggested that it might be effective in this condition.
Our early experience of its use in patients with resistant photo or pattern sensitivity suggests that it may be highly effective in this condition, used in conventional doses. Since, at the moment, the drug is not licensed for generalised epilepsies our use of it in this condition is outwith the license. We suggest formal trials of levetiracetam against photo and pattern sensitivity as soon as possible. The literature suggests that women with epilepsy should escalate the dose of their anticonvulsant during pregnancy particularly during the third trimester (Betts and Crawford, 1998) . Pregnancy causes changes in protein binding of drugs, in liver metabolism, a increased plasma volume, cardiac output and body water. Lamotrigine is being increasingly used in monotherapy in women with epilepsy preconceptually (Betts and Fox, 1999) and therefore an increasing number of women taking lamotrigine will go through pregnancy. We have audited our recent experience of such women.
Use of lamotrigine in monotherapy in
This audit suggests that to keep the patient seizure free or having no more seizures than usual, the dose of lamotrigine needs to be increased during pregnancy sometimes by more than twofold: this dose escalation may need to be started sooner in the pregnancy than previous experience would suggest. Since, like many AEDs, lamotrigine has a neurotoxic threshold, once the baby is born, the dose of lamotrigine may need to be reduced rapidly very shortly after the birth, if neurotoxic symptoms (ataxia, nausea, diplopia) are to be avoided: this is not always necessary.
In patients who were seizure free, blood level monitoring of lamotrigine was used to try to preserve seizure freedom: our impression is that blood level monitoring may not be of much help, but a formal study will be needed to test this properly starting very early in pregnancy and with a baseline blood level. The introduction of levetiracetam onto the UK market has enabled us to test its efficacy in this condition further. We report our total experience of this drug both in open trials and as prescribed medication in 24 patients with this condition. 15/24 patients became totally seizure-free (in particular losing their morning jerks which are sometimes difficult to control with conventional medication). 7 had at least a 50% reduction in seizures: only 2 failed to respond.
Although marketed levetiracetam is not currently licensed for patients with primary generalised epilepsy we will continue to use it because of our audited experience. Formal trials of levetiracetam in this condition are long overdue.
Audit of early clinical experience of the new anticonvulsant levetiracetam (Keppra)
Tim Betts, Kate Smith, Lorna Pritchett, Vanya Ellens, Lyn Greenhill & Mary Eaton
Birmingham University Seizure Clinic, Queen Elizabeth Psychiatric Hospital, Birmingham, B15 2QZ, UK In clinical trials levetiracetam has been shown to be an effective anticonvulsant with a low side effect profile. Clinical trials, however, are carried out in patients with resistant epilepsy and who are carefully selected for exclusion criteria. They do not represent the normal run of patients to be encountered in an epilepsy clinic.
Since its introduction onto the UK market in November, because of its promising profile, we have been using it extensively in our clinic and have been auditing the results. Our early experience, in the first 45 patients to be given the drug, and who have been taking it for long enough for full evaluation, confirms the impression from clinical trials that it is highly effective, rendering 51% of these patients seizure free. Of particular interest is that 67% of patients with primary generalised epilepsy became seizure free (only 37.5% of those with partial onset epilepsy did so). It has an acceptable side effect profile with only three patients withdrawing because of side effects (nausea and ataxia). It is clearly a broad-spectrum drug. We would urge formal clinical trials of its use in primary generalised epilepsy as soon as possible.
Our early experience is promising, but it will take more time to determine whether the initial good effects can be maintained, or whether tolerance will develop. Indications for VNS to date include non-response to existing anti-epileptic (poly) drug therapy. Other possible indications involve epilepsy syndromes not conducive to epilepsy neurosurgery-based treatments, or patient resistant to neurosurgical interventions. Epilepsy populations with associated organic brain syndromes-such as frequently linked to Mental Retardation (ICD10 F72) and Learning Disabilities-also form possible indications.
This report briefly reviews the putative mechanisms of actions of VNS, reviews existing efficacy and safety data, and describes a single case of a right-handed male with localisation related epilepsy syndrome of temporal lobe type, secondary generalisation, significant impulsive aggressive conduct, unipolar depressive episodes and associated borderline learning disability.
Twelve months following implantation of a neurocybernetic prosthesis (NCP) the patient is euthymic, has no further suicidal and deliberate self-harm cognitions, has markedly reduced impulsive assaultative conduct, and has improvement in seizure frequency and seizure semeiology.
Implications for NCP implantation will be discussed, particularly with a view to epilepsy populations with associated and complex neuro-psychopathologies. Methods: Randomized placebo controlled trials recruiting patients with drug-resistant partial seizures were included. Search strategy included contacting UCB Pharma, searching Cochrane Library (Issue 3, 2000) , and Specialist trial register of the Cochrane Epilepsy Group. Outcomes were (a) 50% or greater reduction in seizures (responders), (b) treatment withdrawal, (c) side-effects. Data were combined in meta-analysis. Results are presented as odds ratios with 95% (outcomes (a) and (b)) and 99% (outcome (c)) confidence intervals.
Results: Four trials (1023 patients) were included for treatment withdrawal and side-effect outcomes. Three (904 patients) were included for 50% responders. The overall OR (95% CI) for 50% responders was 3.81 (2.78, 5.22), and for treatment withdrawal was 1.25 (0.87, 1.80). For side-effects, the followings were significantly associated with levetiracetam: dizziness 2.36 (1.21, 4.61) and infection 1.82 (1.05, 3.14). Accidental injury was significantly associated with placebo 0.55 (0.32, 0.93).
Conclusions:
Levetiracetam has add-on efficacy on drug-resistant partial epilepsy, and seems well tolerated. The trials reviewed were of short duration (16-24 weeks), and results cannot be used to confirm long-term efficacy. Results cannot be extrapolated to monotherapy or to other seizure types or syndromes. Photosensitive epilepsy (PSE), which predominately affects females, is usually treated with sodium valproate. However, sodium valproate has been shown to have an adverse side-effect profile, including teratogenicity, and may be associated with the expression of the polycystic ovary syndrome. It is clear, therefore, that an alternative treatment for PSE would be valuable.
The effect of lamotrigine on photoparoxymal responses in the EEG
We have investigated the effect of lamotrigine on photoparoxysmal responses (PPRs) elicited by photic or pattern stimulation in the EEGs of patients with photosensitive epilepsy. Patients were followed up for 12 months whilst they transferred from sodium valproate to lamotrigine, or commenced lamotrigine monotherapy.
Results show that patients changing from sodium valproate can achieve equal control with lamotrigine, as indicated by the EEG.
In patients commencing lamotrigine monotherapy PPRs elicited by photic stimulation are more responsive to lamotrigine than those evoked by pattern stimulation. In a subgroup of patients commencing lamotrigine, abnormal occipital-posterior temporal activity replaces the PPRs suggesting that lamotrigine may prevent the generalisation of abnormalities evoked by photic and pattern stimulation. The results suggest that lamotrigine may be an appropriate substitute for sodium valproate in the treatment of photosensitive epilepsy. 
